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Abstract 
Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterised 
by expression of SS18-SSX fusions, where treatment options are limited. To 
identify therapeutically actionable genetic dependencies in SS, we performed 
a series of parallel, high-throughput small interfering RNA (siRNA) screens 
and compared genetic dependencies in SS tumour cells to those in >130 non-
SS tumour cell lines. This identified an unexpected reliance in SS tumour cells 
upon the DNA damage response kinase, ATR. Clinical ATR inhibitors (ATRi) 
also elicited a synthetic lethal effect in SS tumour cells and impaired the 
growth of SS patient-derived xenografts, suggesting this effect might have 
therapeutic potential. Oncogenic SS18-SSX family fusion genes alter the 
composition of the BAF chromatin-remodelling complex, causing ejection of 
wild-type SS18 and the tumour suppressor SMARCB1 from BAF and their 
eventual degradation. We found that expression of oncogenic SS18-SSX 
fusion proteins caused profound ATRi sensitivity and a reduction in SS18 and 
SMARCB1 protein levels but a SSX18-SSX1 '71-78 fusion with a C-terminal 
deletion did not, thus establishing a causative link between oncogenic SS18-
SSX fusion genes and ATRi sensitivity. ATRi sensitivity in SS was 
characterised by an increase in biomarkers of replication fork stress 
(increased JH2AX, decreased replication fork speed and increased R-loops), 
an apoptotic response and was found to be dependent upon Cyclin E 
expression. Finally, we found that combinations with cisplatin or PARP 
inhibitors enhanced the anti-tumour cell effect of ATRi, suggesting that either 
single agent ATRi or combination therapy involving ATRi might be further 
assessed as candidate approaches for SS treatment. 
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Introduction  
Synovial sarcoma (SS) is a rare, yet aggressive and difficult to treat type of 
soft tissue sarcoma (STS) that has a variable age of onset but predominantly 
affects young adults. Although for patients with localized disease, wide 
surgical excision combined with radiotherapy can be curative, recurrent 
disease is common (1). In the metastatic setting, SS patients are treated with 
cytotoxic chemotherapies, including the topoisomerase inhibitor doxorubicin 
and/or the alkylating agent ifosfamide. Recently, the multi-kinase inhibitor 
pazopanib became the first targeted agent to be approved for the treatment of 
advanced SS after failure of anthracycline containing chemotherapy (2). 
Despite these multimodal therapy approaches, the outcome of metastatic SS 
patients remains poor; those with distant metastasis have a 10-year survival 
rate of only 8.9% compared to 69% for patients with localized tumours (3). 
These factors highlight that additional, more specific therapeutic approaches 
with greater efficacy are required to effectively manage this disease. 
 
The main pathological driver event in SS is known, suggesting that in principle 
at least, mechanism-based targeted approaches to treating SS could be 
developed. The majority of SS are characterised by a t(X;18) reciprocal 
chromosomal translocation, often used as a diagnostic biomarker for the 
disease (4). These t(X;18) translocations fuse the first 10 exons of the SS18 
(synovial sarcoma translocation, chromosome 18) gene to the last three 
exons of one of the SSX (synovial sarcoma, X breakpoint) family of genes, 
SSX1, SSX2 or SSX4 (4, 5), encoding either SS18-SSX1, SS18-SSX2, or 
SS18-SSX4 fusion proteins. SS display few other recurrent mutations (6). 
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A number of studies have aimed to identify the cellular functions of these 
oncogenic fusions as well as of their wild-type SS18 and SSX counterparts (7, 
8). SS18-SSX oncoproteins contribute to the dysregulation of gene 
expression through association with SWI/SNF (BAF) and Polycomb chromatin 
remodelling complexes (9-11). BAF complexes mediate nucleosome 
remodelling via an ATP-dependent process and in doing so modulate 
transcription (12, 13), DNA repair and the maintenance of genomic integrity 
(13, 14). SS18-SSX1 fusion proteins displace wild-type SS18 and an 
additional BAF component, the tumour suppressor SMARCB1, from BAF 
complexes (7). The displacement of SMARCB1 from BAF leads to its 
proteasomal degradation, with reduced levels of BAF-associated SMARCB1 
being a characteristic of SS tumour cell lines and tumours (7, 15).  
 
Despite an enhanced understanding SS18-SSX function, therapeutic targeting 
of these oncogenic proteins has not yet been achieved. One of the more 
recently used approaches to identifying therapeutic targets in cancer has 
been to identify and exploit genetic dependencies, such as synthetic lethal 
and gene addiction effects, that are associated with particular cancer driver 
gene defects. The potential of such an approach is best exemplified by the 
use of small molecule PARP inhibitors in BRCA1/2 mutant cancers (16, 17). 
Since the key driver genotype of SS is well-established, we sought to apply a 
similar approach to identify synthetic lethal interactions in SS. This identified 
an unexpected dependency in SS tumour cells upon on the kinase ATR 
(Ataxia Telangiectasia mutated and Rad3-related), a key mediator of the DNA 
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damage response (DDR) (18) that can be exploited with clinical ATR 
inhibitors. 
 
Materials and Methods 
Cell culture 
Yamato-SS and Aska-SS cell lines were kindly provided by Kazuyuki Itoh and 
Norifumi Naka (Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Osaka, Japan); Akira Kawai (National Cancer Center Hospital, 
Tokyo, Japan) provided SYO-1 cells and Cinzia Lanzi (Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan, Italy) provided CME-1 cells. HS-SY-II 
cells were obtained from the RIKEN BioResource Center. HCT116 WT and 
ARID1A-mutant isogenic cell lines have been described previously (19); all 
other cell lines were supplied by ATCC. Cells were grown in 5% CO2 at 37°C 
in media described below, supplemented with 15% (HFFI) or 10% (all other 
cell lines) fetal calf serum (FCS, Gibco) and 1% Pen-Strep (Sigma). Media for 
cell lines was as follows: Yamato-SS = Dulbecco’s Modified Eagle Medium 
(DMEM; Gibco); Aska-SS= DMEM; SYO-1= DMEM; CME-1 = RPMI 1640 
Medium (Gibco); HS-SY-II = DMEM; HCT116 = McCoy’s 5A Medium (Gibco); 
U2OS = DMEM; HFF1 = DMEM. All cell lines were obtained between 2010 
and 2016 and their identities were confirmed by in-house STR typing and, 
where appropriate, by PCR/Sanger sequencing confirmation of SS-specific 
gene fusions. Mycoplasma testing was carried out on each cell line every five 
passages (all negative). Cells were grown for no longer than 25 passages in 
total for any experiment. 
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siRNA screens 
Cells lines were reversed transfected with a Dharmacon SMARTpool 384 well 
plate-arrayed siRNA library designed to target 714 kinases and kinase-related 
genes, 320 Wnt-pathway associated genes, 80 tumour suppressor genes, 
and 480 genes recurrently altered in human cancers (Supplementary Table 1) 
as described in (20). Positive control (siPLK1) and multiple negative controls 
(siCON1 and siCON2; Dharmacon, catalogue numbers D-001210-01-20 and 
D-001206-14-20, and AllStar; QIAGEN, catalogue number 1027281) were 
included on every plate. Transfection reagents were as follows: SYO-1; Aska-
SS; Yamato-SS and CME-1 = RNAiMAX (Invitrogen); HS-SY-II = 
Lipofectamine 2000 (Invitrogen). Screens were performed in triplicate. Cell 
viability was estimated five days after transfection using CellTiter-Glo assay 
(Promega). Data processing and quality controls were performed using the 
cellHTS2 R package as described previously (20, 21). In the case of the 
VX970 resistance screen (Figure 4), 24h after transfection, VX970 (final 
concentration 0.75 μM) or vehicle (DMSO) was added to cells. Cells were 
then exposed to VX970 for four days and viability estimated with CellTiter-Glo 
assay as above. Drug effect (DE) Z-scores were calculated as described 
previously (22). 
 
Chemosensitisation screens, dose/response cell survival assays, 
assessment of apoptosis 
Screens were carried out and analysed as in (22). In brief, SYO-1 and HS-SY-
II cells were exposed to 0.04 μM VX970 plus a drug library of 79 small 
molecules (Supplementary Table 2), in a 384-well-plate format. After five days 
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drug exposure, cell viability was estimated with CellTiter-Glo assay 
(Promega). Screens were carried out in triplicate. For dose/response cell 
survival assays, cells were plated in 384 well plates at 250-500 cells per well, 
and appropriate drug concentrations were added 24 hours later. Cell viability 
was estimated five days later using CellTiter-Glo. For drug combination 
assays, synergy was determined using MacSynergy II (23). Cell apoptosis 
was assessed using the Promega Caspase-Glo 3/7 assay as per the 
manufacturer’s instructions. 
 
Western blotting 
Cells were harvested and lysed using NET-N lysis buffer supplemented with 
protease and phosphatase inhibitors (Roche) and sonicated for five seconds. 
10-30 μg of cell lysate was then diluted in NuPage sample reducing agent 
(Life Technologies) and NuPage SDS sample buffer (Life Technologies). 
Diluted samples were then boiled for 10 minutes and electrophoresed on a 
polyacrylamide gel. Electrophoresed proteins were then transferred onto a 
0.45 μM nitrocellulose membrane (GE Healthcare), after which membranes 
were probed with primary antibody overnight at 4°C (primary antibodies list in 
Supplementary Table 3). Antibody binding was visualised with HRP-
conjugated secondary antibody and SuperSignalTM West Pico 
Chemiluminescent Substrate (Thermo Scientific) and Super-RX X-ray film 
(Fujifilm).  
Lentiviral SS18-SSX expression 
SS18-SSX1, SS18-SSX2 and the SS18-SSX1 '71-78 mutant cDNAs were 
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cloned into the pLX301 lentiviral transfer vector (7). For viral infection, cells 
were plated in 6-well plates and exposed to 0.5 ml lentiviral filtrate. After three 
days, cells were transferred to a T25 flask containing 1 μg/ml puromycin 
(Gibco) to remove non-transduced cells. After three days selection in 
puromycin, cells were harvested and used for further analysis. GFP 
expression was confirmed in GIPZ-infected cells using an EVOS FL 
fluorescence microscope (Life Technologies). 
 
FACS analysis 
Cells were cultured in 6-well plates and exposed to either 0.5 μM VX970 or 
DMSO. Cells were pulse-labelled with EdU for 1 hour prior to fixation in ice-
cold 100% (v/v) ethanol and stored at -20°C until use. EdU was fluorescently 
labelled by conjugation to the Alexafluor-488 fluorophore using the Click-IT 
EdU Flow Cytometry Kit (Life Technologies) according to the manufacturer’s 
protocol. Total DNA content was assessed by incubation of cells for 15 
minutes in 1.43 μM DAPI (Sigma) in PBS. Cell cycle profiles were generated 
using a BD LSR-II flow cytometer (BD Biosciences) and analysis performed 
using BD FACSDIVA software V8.01. Flow cytometry was performed 
according to the manufacturer’s guidelines. 
 
Immunofluorescent imaging 
Cells were plated onto poly-L-lysine Cellware 12mm round microscope cover 
slips (Corning) in 6-well plates and allowed to adhere overnight. After drug 
exposure, cells were fixed in 4% (v/v) PFA (Sigma) and permeabilised with 
0.2% (v/v) Triton x100 (Sigma). Cells were then immunostained with 
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antibodies targeting: JH2AX (Millipore, 05–636); 53BP1 (Novus, NB100-304); 
RAD51 (Abcam, AB133534); RNA/DNA hybrids (S9.6 ENH001, Kerafast); 
Nucleolin (Abcam, ab50279); or stained with DAPI. Cells were then 
fluorescent-labelled with secondary antibodies: goat anti-mouse IgG 
(ThermoFisher Scientific, Alexa Fluor 555, A-21424); or goat anti-rabbit IgG 
(ThermoFisher Scientific Alexa Fluor Plus 488, A32731) for 60 min at room 
temperature before mounting on slides. Slides were imaged at 63 x on a Leica 
TCS SP2 confocal microscope. Cells were scored positive for JH2AX if 
greater than five foci could be counted within the DAPI-stained nucleus. Cells 
with pan-nuclear JH2AX staining were scored separately from those with 
JH2AX foci. Approximately 120 cells were scored for JH2AX for each 
condition. For quantification of nuclear S9.6 intensity, 30 individual cells were 
scored per condition, and ImageJ was used to generate nuclear masks based 
on DAPI staining. Nuclear S9.6 fluorescence intensity was then determined by 
subtracting the nucleolin signal and analysing the intensity of the remaining 
S9.6 signal. 
 
DNA fibre analysis 
DNA fibre assays were carried out as described previously (24). 
 
In vivo studies   
In vivo efficacy studies were performed using SA13412 patient-derived SS 
xenografts at Crown Biosciences or using HS-SY-II tumour cells grown 
subcutaneously in the flank of female NOD SCID mice or Balb/C nude mice at 
the ICR, London, respectively. When tumours were established (~80 mm3), 
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mice were randomised into treatment and vehicle groups. Animals bearing 
SA13412 PDXs were treated with either vehicle alone or VX970 (60mg/kg; 
oral 4 consecutive days/week) (n=10 per group). Animals bearing HS-SY-II 
tumours were treated with vehicle, VX970 monotherapy (60 mg/kg; oral 4 
consecutive days/week), cisplatin monotherapy (3 mg/kg; intraperitoneally 
once weekly) or the combination (n=6-7 per group). Mice were treated until 
study end (6-12 weeks) or when the maximum tumour size was reached 
(defined as tumour size >15 mm in any direction for HS-SY-II experiments; or 
tumour volume >2000 mm3 for SA13412 PDX experiments). The SA13412 
PDX study was carried out in accordance with the Guide for the Care and Use 
of Laboratory Animals of the National Institutes of Health, USA, and the HS-
SY-II experiment in accordance to ARRIVE guidelines, regulations set out in 
the UK Animals (Scientific Procedures) Act 1986, and in line with a UK Home 
Office approved project licence held by CJL and approved by the ICR ethics 
board. 
 
Results 
RNA interference profiling of SS cell lines identifies ATR as a candidate 
genetic dependency 
To identify candidate therapeutic targets in SS, we carried out large-scale 
small interfering RNA (siRNA) screens in five commonly-used SS tumour cell 
lines; HS-SY-II, Aska-SS, Yamato-SS, CME-1 and SYO-1 (Figure 1A). These 
cell lines were selected as they harbour either one of the two most common 
SS-associated fusions (SS18-SSX1 or SS18-SSX2), and were amenable to 
high-efficiency siRNA transfection in a 384-well plate format (Figure 1B-D). 
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After optimising high-throughput transfection conditions, each cell line was 
reverse-transfected with a 384-well plate-arrayed siRNA library designed to 
target 1600 genes (Supplementary Table 1 and Methods), including 
pharmacologically tractable kinase-coding and kinase-related genes, Wnt-
pathway-associated genes given their role in SS (11, 25, 26) and genes 
recurrently altered in human cancers (27). Cell viability was measured after 
five days and this data then used to identify those siRNAs that caused 
significant tumour cell growth inhibition (i.e. genetic dependencies). Robust Z-
scores were calculated from three replica screens (Methods and 
Supplementary Table 4) to estimate the effect of siRNAs on tumour cell 
inhibition. 
 
To identify genetic dependencies associated with SS, we compared the 
siRNA Z-scores from the SS tumour cell line screens to siRNA Z-score 
profiles of >130 tumour cell lines from a diverse set of cancer histotypes (20). 
We noted a series of profound SS-specific genetic dependencies, including 
the proto-oncogene Mouse Double Minute 2 homologue (MDM2), the gene 
encoding the calcium-binding protein Calmodulin (CALM1) (Figure 1E,F), 
genes associated with Wnt-signalling (e.g. those encoding the Wnt ligand 
WNT7B and the E-catenin interacting protein, BCL9L (28) Figure 1G,H) and 
the druggable Never in Mitosis-A (NIMA) family members (29) NEK1, 2 and 4 
(Figure 1I-K). The substantial variation in siRNA Z-scores within the SS 
tumour cell lines for these genes however suggested that these were not 
highly penetrant effects (i.e. profound effects in the vast majority of SS tumour 
cell lines) and might therefore have limited utility as targets in SS. More 
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penetrant genetic dependencies associated with SS included the DREAM 
complex kinase, DYRK1A (Figure 1L) and the DNA Damage Response (DDR) 
kinase ATR (Figure 1M, described below). DYRK1A inhibition is synthetic 
lethal with RB1 (pRb) tumour suppressor defects in osteosarcoma (OS) (20). 
We found the sensitivity of SS tumour cell lines to DYRK1A siRNA to be of a 
scale equivalent to that in RB1 null OS tumour cell lines (Figure 1L), 
suggesting that DYRK1A, which is amenable to small molecule inhibition (20, 
30), might be worthy of further assessment as a candidate therapeutic target 
in SS. 
 
We also found a series of genes involved in the DNA Damage Response 
network (DDR) (31) to be candidate genetic dependencies in SS, including 
ATR, the ATR-activating proteins RAD9A and RAD18, and two tumour 
suppressor genes involved in double strand break repair by homologous 
recombination (HR), BRCA1 and BRCA2 (Figure 1M-Q), suggesting a 
reliance upon processes that are associated with the stability and repair of 
replication forks. 
 
ATR genetic dependency in SS can be elicited with clinical ATR 
inhibitors  
The identification of ATR as a candidate genetic dependency was particularly 
interesting for a number of reasons: (i) compared to other cancer histologies, 
we found the five SS tumour cell lines to be amongst the most sensitive 
tumour cell lines to ATR siRNA and to respond in a relatively consistent 
fashion (Figure 2A), suggesting a relatively penetrant effect; (ii) relatively little 
is understood about the sensitivity of SS tumours to small molecule DDR 
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inhibitors, such as ATR inhibitors; and (iii) ATR inhibitors such as VX970 and 
AZD6738 have recently entered clinical trials for cancer treatment (e.g. 
clinicaltrials.gov NCT02157792, NCT02223923), suggesting that this genetic 
dependency could be clinically actionable.  
 
Having confirmed the sensitivity of SS tumour cell lines to ATR siRNA in post-
screen validation experiments (Supplementary Figure 1A-C), we assessed the 
sensitivity of the five SS tumour cell lines to the clinical ATR inhibitor (ATRi), 
VX970 (Vertex Pharmaceuticals/Merck KGaA). Compared to previously-
validated ATRi resistant HCT116 colorectal cancer cells (32), all five SS cell 
lines were profoundly sensitive to VX970 (ANOVA p<0.0001), each exhibiting 
SF50 (concentration required to cause 50% reduction in cell survival) values of 
≈ 0.1 PM (Figure 2B). SS tumour cell lines were also more sensitive to ATRi 
compared to HFF1 fibroblasts and non-tumour epithelial MCF10A cells 
(Supplementary Figure 1D). Defects in the tumour suppressor gene ARID1A 
cause ATRi sensitivity, both in vitro and in vivo (32). We found SS tumour cell 
lines to be as sensitive to VX970 as ARID1A-defective HCT116 cells 
(HCT116ARID1A–/–) (19) (Figure 2C). Furthermore, when comparing the VX970 
sensitivity of SS tumour cell lines to those with other molecular defects 
associated with ATRi sensitivity, namely ATM gene defects (33), ARID1A 
mutations (32) and Ewing’s sarcoma (EWS) associated EWS-FLI fusions (34), 
the SS tumour cell lines showed a similar extent of VX970-sensitivity to EWS 
tumour cells and ARID1A-defective tumour cells (Figure 1D, Supplementary 
Figure 1E). This consistent in vitro sensitivity of SS tumour cell lines to ATRi 
was also observed with other ATR inhibitors, including the clinical ATRi 
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AZD6738 (35) (AstraZeneca) and the toolbox inhibitors AZ20 (35) 
(AstraZeneca) and VE821 (36) (Vertex Pharmaceuticals) (Supplementary 
Figure 1F-H), suggesting that these effects were not specific to VX970 and 
represented a drug class effect. We next assessed whether the clinical ATRi 
VX970 could inhibit SS tumour growth in vivo. Treatment of mice bearing 
established patient-derived SS xenografts (PDX SA13412; SS18-SSX1 
translocation-positive) with VX970 caused a significant inhibition of tumour 
growth (ANOVA p<0.0001, Figure 2E) and extended the survival of tumour-
bearing mice (log-rank test p=0.0451, Figure 2F).  
 
SS18-SSX1 or SS18-SSX2 fusion proteins induce ATRi sensitivity and 
reduce SMARCB1 and SS18 protein levels 
To establish a causative link between the expression of oncogenic SS18-SSX 
fusions and ATRi sensitivity, we ectopically expressed SS18-SSX1 or SS18-
SSX2 cDNAs in cells and assessed ATRi sensitivity. Many cell lines, including 
HFF1 fibroblasts, were unable to maintain long-term survival in the face of 
either SS18-SSX1 or SS18-SSX2 cDNA expression, precluding the use of 
these models in drug sensitivity assays where prolonged cell culture is 
required. However, we found that ATRi resistant HCT116 cells were able to 
tolerate lentiviral expression of SS18-SSX1 or SS18-SSX2 cDNA 
(Supplementary Figure 2A-C). Furthermore, expression of SS18-SSX1 or 
SS18-SSX2 in HCT116 cells recapitulated three features previously 
associated with SS fusion gene expression, namely: (i) a modest reduction in 
endogenous SS18 expression (7); (ii) a reduction in levels of the SWI/SNF 
component SMARCB1 (7); and (iii) upregulation of the canonical Wnt-pathway 
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target gene AXIN2 (Figure 2G-H), effects replicated in short-term U2OS 
(osteosarcoma) and HFF1 (fibroblast) cell cultures (Supplementary Figure 2C-
E). Amino acid residues at the C-terminus of the SS18-SSX1 fusion protein 
are critical for the displacement of SMARCB1 from SWI/SNF complexes (7). 
In comparison to the expression of full-length SS18-SSX1 or SS18-SSX2 
fusion proteins, expression of an SS18-SSX1 variant with the final eight 
residues of SSX1 deleted ('71-78) did not cause a reduction in SMARCB1 
levels, nor an increase in AXIN2 mRNA (Figure 2G-H). Having established 
that SS18-SSX fusion expression could recapitulate some of the molecular 
features associated with SS fusion gene expression, we assessed the effects 
of these fusions upon ATRi sensitivity. We found both SS18-SSX1 and SS18-
SSX2 cDNAs caused a significant (ANOVA p<0.0001) enhancement in 
sensitivity to a series of distinct ATR inhibitors, whereas the expression of the 
SS18-SSX1 '71-78 mutant isoform did not (Figure 2I-K), establishing a 
causative link between the expression of oncogenic fusion genes and ATRi 
sensitivity. Furthermore, siRNA mediated gene silencing of SMARCB1 in 
HCT116 cells also caused VX970 sensitivity (ANOVA, p<0.001, 
Supplementary Figure 2F,G), suggesting that the SWI/SNF defect caused by 
SS fusion genes could, in principle, be responsible for ATR inhibitor 
sensitivity. 
 
As defects in DNA damage response pathways, such as ATM and ATR 
activation, have been associated with increased ATRi sensitivity (33, 37), we 
assessed whether defects in ATM/ATR activation following DNA damage in 
SS tumour cell lines could explain the ATRi sensitivity. However, we did not 
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detect a profound dysfunction in the ability of SS tumour cells to elicit ATR 
signalling in response to either cisplatin or hydroxyurea, or ATM signalling in 
response to ionising radiation (IR) (Supplementary Figure 3A-C). 
Furthermore, we found that SS tumour cells generated nuclear RAD51 foci in 
response to ATRi, hydroxyurea or IR (Supplementary Figure 3D), suggesting 
that a defect in RAD51-mediated DNA repair processes might not explain 
ATRi sensitivity. ATRi sensitivity has also been associated with a reduction in 
chromatin bound topoisomerase levels (32). Again, we did not observe a clear 
defect in chromatin-TOP2A levels that could explain the profound ATRi 
sensitivity (Supplementary Figure 3E-J). 
 
ATRi causes apoptosis and replication fork stress in SS tumour cells  
In addition to ATR, our siRNA screens suggested that SS tumour cells were 
also reliant upon additional proteins involved in the replication fork stress 
response, including RAD9A and RAD18 (Figure 1N-O). As well as finding that 
SS tumour cells exposed to ATRi exhibited biomarkers of an apoptotic 
response (caspase 3/7 and PARP1 cleavage (Figure 3A-B)), we noted that 
ATRi induced pan-nuclear phosphorylation of histone H2AX (JH2AX), which is 
a biomarker of replication fork stress (Figure 3B-E). To assess the replication 
fork stress phenotype in more detail, we used DNA fibre analysis (24) and 
found that VX970 exposure caused a significant reduction in replication fork 
speed in SYO-1 SS tumour cells (p<0.0001, paired t-test, Figure 3F, 
Supplementary Figure 4A-B). In addition, ectopic expression of SS18-SSX1 
fusion protein in HCT116 cells caused a modest but significant decrease in 
replication fork speed (p<0.0001, paired t-test), an effect enhanced by 
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exposure to VX970 (Figure 3G, Supplementary Figure 4C). This suggested 
that the SS18-SSX1 fusion protein might cause an increase in replication fork 
stress, which is in turn enhanced by ATR inhibition. One cause of replication 
fork stress is steric interference between DNA replication and transcriptional 
machineries, often associated with R-loops, DNA-RNA hybrid structures that 
activate ATR-mediated DNA damage responses (38). We reasoned that an 
enhanced transcriptional programme caused by SS fusion expression might 
cause R-loops. R-loop frequency can be estimated by the 
immunohistochemical detection of DNA-RNA hybrid structures (38). We found 
that the exposure of SYO-1 cells to VX970 enhanced the R-loop IHC signal 
(p<0.001, Student’s t-test, Figure 3H). The expression of the SS18-SSX1 
fusion in HCT116 cells also caused a modest but significant increase in R-
loop IHC signal (p<0.001, Student’s t-test), which was enhanced by the 
addition of VX970 (p<0.001, Student’s t-test, Figure 3I). 
As previous studies have demonstrated that ATRi prevents normal replication 
of DNA under oncogene-induced replication fork stress (39), we performed 
FACS cell-cycle analysis to determine whether a similar effect operated in SS 
cells. SYO-1 cells were pulse-labelled with EdU, which is incorporated into 
DNA during active DNA synthesis. Cells exposed to VX970 exhibited a 
profound reduction in the fraction of cells in active S-phase (from 30% to 8% 
after 48 hours VX970 exposure (Figure 3J, Supplementary Figure 4D)), 
suggesting that ATRi exposure in SS tumour cells impaired DNA replication, 
consistent with our previous observations. 
 
ATRi sensitivity in SS tumour cells is Cyclin E dependent 
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To gain more insight into the processes involved in ATRi sensitivity, we took a 
relatively unbiased approach using an siRNA “resistance” screen to identify 
genes that could reverse the ATRi sensitivity phenotype in a SS tumour cell 
line. SYO-1 cells were reverse-transfected in a 384-well plate format with the 
siRNA library described earlier, and 24h later exposed to either a relatively 
high concentration of VX970 (0.75 μM) or vehicle (DMSO) for four continuous 
days (Figure 4A). Results of three highly correlated replica screens were 
combined in the final analysis. By comparing siRNA effects in VX970-exposed 
vs. DMSO-exposed cells we identified those siRNAs that caused VX970 
resistance (see Methods), quantifying resistance-causing effects as Drug 
Effect (DE) Z-scores (Supplementary Table 5, Figure 4B). The most profound 
ATRi resistance-causing effect identified in this screen was caused by siRNA 
designed to target the Cyclin E encoding gene CCNE1 (Figure 4B, DE Z-
score 7.7). Multiple independent CCNE1 siRNAs derived from the 
SMARTpool reduced Cyclin E protein expression (Figure 4C), and caused a 
statistically significant reduction in ATRi sensitivity in subsequent dose-
response survival assays in both SYO-1 and HS-SY-II SS cells (Figure 4D-E, 
ANOVA p<0.0001). We found that the CCNE1 siRNA SMARTpool used in the 
siRNA screen also reduced the extent of VX970-induced apoptosis in SYO-1 
cells (Figure 4F). As Cyclin E has been implicated in enhancing replication 
fork stress (40, 41), we next tested the ability of CCNE1 siRNA to reverse the 
JH2AX response to ATRi exposure. We found that CCNE1 siRNA reduced 
both JH2AX and RPA phosphorylation in response to ATRi exposure (Figure 
4G), an observation also reproduced by immunofluorescent detection of 
JH2AX (Figure 4H). However, Cyclin E protein expression itself was not 
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regulated by ectopic expression of SS18-SSX1, SS18-SSX2 or SS18-SSX1 
'71-78 fusions (Supplementary Figure 4E). Several likely explanations might 
account for the role of Cyclin E in these phenotypes; the presence of a SS 
fusion gene might create a genomic context (e.g. a chromatin remodelling 
event) that allows Cyclin E to mediate replication fork stress. Alternatively, the 
reduction in Cyclin E expression in SS tumour cells might independently 
reduce or delay entry into S phase, thus minimising the effects of an ATR 
inhibitor that would otherwise mediate its cytotoxic effects by targeting cells 
undergoing DNA replication. Indeed, we found that CCNE1 siRNA reduced 
the fraction of SS tumour cells in S phase (Supplementary Figure 4F,G), 
although such an observation might not completely discount the possibility 
that Cyclin E in S-phase might also play a role in ATRi sensitivity in SS cells 
 
Identification of candidate drug combinations with ATR inhibitors in SS 
To improve the likelihood of a significant and sustained clinical response to 
ATR-targeted therapy, we also assessed the effects of combination therapy 
approaches with ATRi in SS tumour cells. To do this, we used high-
throughput chemosensitisation screens in SYO-1 and HS-SY-II cells to 
identify ATRi combinatorial effects. Here, we used a bespoke drug library 
encompassing 79 different small molecules, which are either already used in 
cancer treatment or are in late-stage development (see Methods). To 
maximize the possibility of identifying drug combination effects, each small 
molecule in the library was used in eight concentrations (see Methods). From 
this screen, we identified several drugs that sensitised both SYO-1 and HS-
SY-II cells to VX970. These included the three clinical PARP1 inhibitors 
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rucaparib, olaparib and talazoparib (BMN673), the WEE1 kinase inhibitor 
MK1775, the CHK1 kinase inhibitor SAR20106, the Topoisomerase inhibitor 
camptothecin and the replication inhibitor sapacitabine (Figure 5A-B), all 
agents that either cause and/or enhance replication fork stress. In validation 
experiments in a third SS tumour cell line, Yamato-SS, we found that the 
addition of either olaparib or talazoparib enhanced the effects of VX970 
(Figure 5C-D). Synergistic effects of combined ATR and PARP inhibition have 
been reported in other tumour types as well (42-44). 
We also assessed known synergistic combinations with ATRi, as well as 
assessing the effects of combining ATRi with standard-of-care agents used in 
SS. For example, in non-SS tumour cells, the combination of VX970 with 
platinum salts has been reported as synergistic (33); we found that the 
combination of VX970 and cisplatin generated a synergistic effect on cell 
inhibition in both SYO-1 and HS-SY-II cells, generating synergy volumes of 
465 μM2 and 334 μM2, respectively (Figure 5E-H). This combinatorial effect 
also elicited a survival benefit in mice bearing HS-SY-II SS tumour xenografts 
(p=0.0424, log-rank test, Figure 5I). Finally, we also assessed combinations 
of VX970 when used with cytotoxic agents used in the treatment of SS 
(doxorubicin and the alkylating chemotherapeutic cyclophosphamide) as well 
as the targeted drug used in SS treatment pazopanib (2). We observed 
largely non-synergistic effects in each of these cases, although in HS-SY-II 
cells, the combination of VX970 plus the active derivate of cyclophosphamide 
(4-HC) caused a mild synergistic effect (Supplementary Figure 5).  
  
ATR is a therapeutic target in synovial sarcoma   
 
22 
Discussion 
In this study, high-throughput siRNA screening of SS cell lines identified a 
selective and novel dependency upon the DDR-related kinase ATR. 
Validation studies confirmed a synthetic lethal interaction between SS18-SSX 
fusion genes and ATR and established that ATRi might be used to exploit this 
effect. 
The sensitivity of SS to DDR-targeting drugs was rather unexpected. To date, 
much of the focus on identifying tumour subtypes that might respond to 
targeted DDR targets has centred upon tumour subtypes such as high-grade 
serous ovarian cancers, where homologous recombination (HR) defects with 
expected genomic rearrangements exist (31). Although genomic instability 
has been reported in SS, this is generally restricted to adult patients and 
those with advanced disease; the majority of patients with SS have tumours 
that do not exhibit mutations or chromosomal alterations other than a 
pathognomonic SS18-SSX translocation (6, 45, 46). Interestingly, ATRi 
sensitivity has also been recently reported in models of Ewing’s sarcoma, a 
sarcoma of adolescent and young adult (AYA) age that is generally 
characterised by a single oncogenic fusion driver event (EWS-FLI 
translocations) (34). In our in vitro assays, SS cells appeared to have 
comparable ATRi sensitivity to EWS-FLI1 positive Ewing’s sarcoma tumour 
cells. This might suggest that assessing ATR inhibitor sensitivity in additional 
AYA and/or other translocation-associated sarcoma subtypes might also 
identify similar vulnerabilities. 
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At the mechanistic level, our data suggest that the expression of SS18-SSX 
fusion genes generates a relatively moderate form of replication fork stress 
that is enhanced by ATR inhibition (for example, Figure 3F-G). Our analysis of 
ATRi sensitivity in SS tumour cells suggests that this phenotype is dependent 
on a known mediator of replication fork stress, Cyclin E (40, 41), (Figure 4) 
but is not necessarily caused by an overt increase in Cyclin E expression, 
profound defects in either ATM, ATR or chromatin bound topoisomerase 
levels or a defect in RAD51 localisation to the site of DNA damage 
(Supplementary Figure 3). Another possibility might be that the expression of 
SS fusion genes and the subsequent effects on SWI/SNF function cause 
subtle yet critical differences in the chromatin structure of the genome that 
induces an increased impairment of replication fork progression and thus an 
enhanced reliance upon ATR (and sensitivity to ATRi); this model would be a 
form of induced essentiality (47).  
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Figure legends 
Figure 1. Genetic dependency profiling in synovial sarcoma cells 
identifies ATR as a candidate genetic dependency 
A. Overview of the five SS cells lines and their characteristic SS18-SSX driver 
fusions. B. Schematic of siRNA screening procedure and data processing. C. 
Scatter plot illustrating distribution of siRNA Z-scores for negative (siCON1, 
siCON2 and AllSTAR) and positive (siPLK1) controls, as well as Z-scores for 
the library siRNAs in the SYO-1 siRNA screen. Dots represent siRNA Z-
scores from individual wells in the library. Each well contained a siRNA 
SMARTPool designed to target one gene. Error bars represent standard 
deviation. D. Scatter plot illustrating the correlation of siRNA Z-scores 
between replica 1 and replica 2 in the SYO-1 screen. E-Q. siRNA Z-score 
plots illustrating genetic dependencies associated with SS. Error bars 
represent standard deviation from median effects. p-value represents Mann-
Whitney test. 
 
Figure 2. ATRi sensitivity is caused by SS fusion proteins 
A. Summary of siRNA Z-scores from the siRNA screen for ATR in cell lines – 
tumour cell lines are classified by cancer of origin. Error bars represent 
standard deviation. p-values were calculated using Mann-Whitney test. B. 
Dose-response curves from five-day survival assays, illustrating the sensitivity 
of SS tumour cell lines to the clinical ATR inhibitor VX970. ATRi resistant 
HCT116 cells were used as a negative control. p-value represents 2-way 
ANOVA compared to HCT116 cells. Error bars represent standard deviation 
(SD) from triplicate experiments. C. Dose-response curves from five-day 
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survival assays, illustrating the ATRi sensitivity of SS tumour cell lines 
compared to HCT116 ARID1A+/+ and ARID1A-/- isogenic cell lines. p-value 
represents 2-way ANOVA compared to HCT116 ARID1A+/+ cells. Error bars 
represent SD from triplicate experiments. D. Area Under Curve (AUC) values 
for SS tumour cell lines screened for sensitivity to VX970 in five-day survival 
assays compared to non-SS tumour cells (“other”), ATM defective, ARID1A 
defective or Ewing’s sarcoma (EWS) tumour cell lines. p-values represent 
Mann-Whitney test. Error bars represent standard deviation. E. Tumour 
inhibition elicited by VX970 treatment in established SS PDX tumours. Mean 
relative tumour volume plot showing efficacy of VX970 (60mg/kg; oral 4 
consecutive days/week) in SA13412 SS PDX models. p-values represent 2-
way ANOVA of VX970-treated mean relative tumour volumes versus controls 
after 48 days treatment. Error bars represent standard error of the mean. F. 
Kaplan-Meier curves for tumour-size-related survival (defined by a tumour 
reaching volume of 2000mm3) demonstrating a significant delay in time to 
reach the tumour size limit in the VX970 treatment group as compared to 
controls. p-value represents log-rank test. G. Western blot illustrating ectopic 
expression of SS18-SSX1, SS18-SSX2 and '71-78 (d71-78) fusions in 
HCT116 cells. Ectopic expression of SS18-SSX1 and SS18-SSX2 reduced 
SMARCB1 protein levels. “Empty” = expression vector without cDNA insert. 
H. Bar chart illustrating the effect of SS18-SSX1, SS18-SSX2 and '71-78 
(d71-78) fusions on transcription of the Wnt target gene AXIN2 in HCT116 
cells. p-values represent Student’s t-test; error bars represent standard 
deviation from triplicate experiments. “Empty” = expression vector without 
cDNA insert. I-K. Dose-response curves illustrating the effect of SS18-SSX1, 
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SS18-SSX2 and '71-78 fusion expression on sensitivity of HCT116 cells to 
AZD6738 (L), AZ20 (M) and VX970 (N) ATR inhibitors. Error bars represent 
SEM from triplicate experiments. p-values represent two-way ANOVA, ns = 
not significant (p>0.05 vs. empty). “Empty” = expression vector without cDNA 
insert. 
 
Figure 3. ATR inhibition causes apoptosis and replication fork stress in 
SS tumour cells  
A. Bar chart illustrating a dose-dependent increase in Caspase Glo activity in 
SYO-1 cells exposed to VX970 for 48h. Caspase Glo luminescence was 
normalized to cell viability as determined by CellTiter-Glo, and calculated as 
fold change compared to DMSO-exposed cells. p-values represent student’s 
t-test. Error bars represent standard deviation. B. Western blot illustrating 
accumulation of cleaved PARP1 and JH2AX upon VX970 exposure in SYO-1 
SS cells. C. Western blot illustrating accumulation of JH2AX after exposure of 
HS-SY-II cells to 500 nM VX970. Two independently-derived lysates were 
generated at each time point as shown. D. Representative confocal 
microscopy images illustrating elevated 53BP1 (green) and JH2AX (red) 
foci/pan nuclear staining in SYO-1 cells following exposure to 500 nM VX970 
(8 hours) or 2 mM hydroxyurea (HU; positive control), compared to DMSO-
exposed controls. E. Bar chart showing percentage of SYO-1 cells with 
elevated JH2AX levels following exposure to 500 nM VX970 (h = hours of 
exposure). 100 images were captured and scored for >5 JH2AX foci or pan-
nuclear JH2AX staining. HU exposure was used as a positive control. All p-
values were calculated using student’s t-tests. Error bars represent standard 
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deviation from triplicate experiments. F. Replication fork rates as measured 
from DNA fibre monitoring in SYO-1 cells exposed to DMSO or 500 nM 
VX970 for 2 hours. At least 100 tracks were measured for each condition. 
Average fork speed SYO-1 exposed to DMSO = 0.51 kb/min, average fork 
speed SYO-1 exposed to VX970 = 0.3 kb/min. Error bars represent standard 
deviation, p-value represents paired t-test. G. Replication fork rates as 
measured from DNA fibre monitoring in HCT116 cells expressing ectopic 
SS18-SSX1 cDNA exposed to DMSO or 500 nM VX970 for 2 hours. At least 
100 tracks were measured for each condition. Error bars represent standard 
deviation, p-values represent paired t-test. H. Box and whisker plot of R-loop 
(S9.6 nuclear staining) intensity in SYO-1 cells exposed to VX970 for 4 hours. 
Nuclear S9.6 staining intensity levels were corrected for S9.6 nucleolar 
intensity. 30 individual cells were scored for each condition. Box represents 
10-90% of data. p-values represent student’s t-test. I. Box and whisker plot of 
R-loop (S9.6 nuclear staining) intensity in HCT116 cells expressing ectopic 
SS18-SSX1 cDNA (“fusion”) exposed to DMSO or 500 nM VX970 for 4 hours. 
p-values represent student’s t-test. “Empty vector” = expression vector without 
cDNA insert. J. Cell cycle profiles for EdU incorporation in SYO-1 cells 
exposed to 0.5 μM VX970. DAPI was used to estimate DNA content. 
Numbers indicate fraction of cells present in the different cell cycle phases 
after 16, 24 and 48 hours VX970 exposure. 
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Figure 4. Sensitivity to ATRi in SS tumour cells is Cyclin E dependent 
A. Schematic illustrating VX970 resistance siRNA screen assay design. SYO-
1 cells were transfected with the siRNA library and then exposed to either a 
high concentration of VX970 (0.75 μM) or DMSO. After four days continuous 
drug exposure, cell viability was assessed. B. Ordered scatter plot illustrating 
ATRi-resistance-causing effects identified in the screen described in (A). The 
effect of each siRNA SMARTpool on drug resistance was estimated by the 
calculation of Drug Effect (DE) Z scores, with DE Z-score > 2 (dashed line) 
regarded as significant effects. The effect of CCNE1 siRNA SMARTpool is 
highlighted. C. Western blot illustrating Cyclin E silencing in SYO-1 cells 
mediated by the CCNE1 SMARTpool (“Pool”) and the four different 
constituent siRNAs (♯1-4). D-E. Dose-response curves showing effect of 
CCNE1 siRNAs on VX970 sensitivity in SYO-1 (D) and HS-SY-II (E) cells. 
ANOVA p-values represent 2-way ANOVA for each siRNA compared to non-
targeting siAllStar. Error bars represent SD from triplicate experiments. F. Bar 
chart illustrating effect of siCCNE1 SMARTpool on apoptosis in SYO-1 cells. 
Apoptosis was measured by Caspase Glo assay after 48 hours of VX970 
exposure. Error bars represent standard deviation from triplicate experiments. 
p values calculated by Student’s t test. G. Western blot showing effect of 
siCCNE1 SMARTpool on JH2AX and pRPA following 0.5 μM VX970 exposure 
in SYO-1 cells for 8 or 24 hours. H. Bar chart showing effect of siCCNE1 on 
accumulation of pan-nuclear JH2AX and foci after 24h exposure to VX970 in 
SYO-1 cells. Error bars represent standard deviation from triplicate 
experiments. p value calculated by Student’s t test. 
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Figure 5. Identification of candidate drug combinations with ATR 
inhibitors in SS 
A-B. Heat maps summarising the results from high-throughput 
chemosensitisation screens using VX970 in SYO-1 (A) and HS-SY-II (B) cells.  
Drug sensitisation effects are shown as Drug Effect (DE) Z-scores for each 
concentration of the top 10 chemosensitising molecules out of 79 library small 
molecules used in combination with VX970. Concentration (nM) denotes the 
concentration of the library small molecules used in combination with VX970. 
Library small molecules are rank ordered top to bottom according to average 
VX970 DE Z-scores; library small molecules causing VX970 
chemosensitisation are ranked at the top of the heat map. C-D. Dose-
response curves in Yamato-SS cells exposed to escalating concentrations of 
VX970 combined with the PARP inhibitors olaparib (C) or talazoparib 
(BMN673) (D) for five days. Error bars represent standard deviation. p-values 
were calculated with a 2-way ANOVA compared to cells exposed to VX970 
alone. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. E-F. MacSynergy 
plots for SYO-1 (E) and HS-SY-II (F) SS cells exposed to escalating 
concentrations of VX970 combined with cisplatin. 3D synergy plots represent 
synergy volumes in PM2; volumes > 120 PM2 were considered as synergistic 
(details in Methods) and are shown in bold. G-H. Dose-response curves for 
SYO-1 (G) and HS-SY-II (H) cells exposed to escalating concentrations of 
VX970 combined with cisplatin. Error bars represent standard deviation. p-
values were calculated with a 2-way ANOVA compared to cells exposed to 
VX970 alone. *p < 0.05; ***p < 0.001; ****p < 0.0001. I. Kaplan-Meier survival 
curves for tumour-size-related survival (defined by a tumour reaching the 
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tumour size limit of 15 mm in any one direction) demonstrating a significant 
delay in time to reach the tumour size limit in the combined treatment group 
as compared to controls. p-value calculated by log-rank test.  





